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Summary
AIMS OF THE STUDY: Premature discontinuation occurs
in about 25% of randomised clinical trials in Switzerland; it
mainly affects investigator-initiated trials and is mostly due
to problems with recruitment of patients. The aim of this
study was to qualitatively investigate reasons for trial dis-
continuation due to poor patient recruitment and sugges-
tions to address those reasons in the Swiss context.
METHODS: We conducted semi-structured interviews
with trialists whose trials were discontinued because of re-
cruitment problems, other experienced trialists, and stake-
holders in clinical research in Switzerland. Interviews were
audio-recorded, transcribed verbatim, and anonymised.
We analysed the transcripts using deductive coding and
built up themes that were continuously discussed within
the research team.
RESULTS: Of 65 invited Swiss trialists and stakeholders,
39 (60%) agreed to be interviewed and contributed to
this analysis. We identified four main themes of reasons
for poor recruitment: (1) Switzerland has a decentralised
healthcare system with many small hospitals and few pa-
tients per hospital, many research regulations, no stan-
dardisation of medical records across hospitals, and a het-
erogeneous ethics assessment of study protocols. There
is little collaboration of different stakeholders in clinical re-
search and a lack of prioritisation of projects. (2) Limited
human and financial resources, especially in the academic
setting, compromise research questions and size of clin-
ical trials. When funding is used up this typically triggers
discontinuation of already delayed clinical trials. (3) In-
vestigators face underdeveloped research networks and
a limited collaborative attitude among clinical researchers.
They typically embark on clinical studies with a great deal
of optimism but insufficient preparation. (4) Swiss patients
have universal health coverage and many treatment op-
tions. Negative media coverage of clinical research and a
lack of accessible information for patients about ongoing
clinical studies frequently make participation in clinical tri-
als less attractive. More interactive structures and collab-
oration across stakeholders were mentioned as potential
solutions to tackle the problems.
CONCLUSIONS: Recruitment of participants into clinical
trials in Switzerland is challenging because of various,
often interlinked factors related to the Swiss health sys-
tem, available funding, investigators, and patients. Com-
mon goals and concerted efforts by involved stakeholders
appear necessary to achieve improvement.
Key words: randomised controlled trials, early termination
of clinical trials, poor recruitment, stakeholder interviews
Introduction
One out of four randomised clinical trials (RCTs) in
Switzerland is prematurely discontinued. This is problem-
atic because study participants may have been exposed to
potential health risks and other burdens of participating in
a trial that was discontinued without the research question
being answered [1]. In addition, scarce research resources
are wasted if RCTs are not completed, and evidence that
may still contribute to systematic reviews and meta-analy-
ses, as well as the root causes behind the discontinuation,
are not published.
In Switzerland, Germany and Canada, the most common
reason for RCT discontinuation is insufficient recruitment
of trial participants, particularly in investigator-initiated
RCTs [1]. Various qualitative and quantitative studies have
already suggested different barriers to and facilitators of
recruitment [2–11]. Most of these studies, however, fo-
cused on specific disciplines or countries other than
Switzerland. In order to find suitable lever points, it is im-
portant to understand the mechanisms and root causes un-
derlying insufficient recruitment to RCTs and to capture
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the views of the full spectrum of involved stakeholders in
the Swiss clinical research arena such as individual inves-
tigators, research networks like the Swiss Group for Clini-
cal Cancer Research (SAKK), the Swiss National Science
Foundation (SNSF), research ethics committees, the clini-
cal trial units (CTUs) federated within the Swiss Clinical
Trial Organisation (SCTO), swissmedic, the pharmaceu-
tical industry and contract research organizations, patient
representatives, and the Federal Office of Public Health
(FOPH).
The present qualitative research was built on the findings
of a retrospective cohort of RCT protocols [1] and a sys-
tematic review that suggested that a large majority of rea-
sons for poor recruitment in RCTs is preventable if thor-
ough feasibility assessment and pilot studies are undertak-
en in advance [12]. The aim of this paper is to elucidate
reasons for trial discontinuation due to poor participant re-
cruitment and to discuss solutions specifically in the Swiss
context.
Materials and methods
No ethics approval was necessary according to the Re-
search Ethics Committee of Northwestern and Central
Switzerland (EKNZ UBE-15/50). This interview study
was considered unproblematic from an ethical point of
view.
Of 65 invited Swiss trialists and stakeholders, 39 (60%)
agreed to be interviewed and contributed to this explo-
ration of reasons for poor recruitment to clinical trials in
Switzerland and ways to prevent it.
Study instrument
We developed a list of open-ended questions to facilitate
in-depth interviews with the respondents. These questions
helped to steer the discussion while providing respondents
with sufficient freedom to describe experiences and per-
spectives that they deemed relevant to our research ques-
tions. We finalised the interview guides with the inputs
from two pilot interviews and feedback from other quali-
tative researchers (see appendix 1 for details of interview
guides).
Interviews and transcription
We identified the respondents through our professional
networks and the list of principal investigators whose trials
were discontinued in the past because of poor recruitment
[1]. Between August 2015 and November 2016, MB and
PS conducted all interviews in English, in person when-
ever possible or by telephone at times convenient to the
respondents. We continued recruitment till theoretical sat-
uration was reached. The latter is defined as the moment
in qualitative research when researchers are convinced that
additional interviews do not generate new themes related
to the research question [13]. We ensured confidentiality
and anonymity of each respondent by removing all person-
al identifiers such as their names, affiliations or profession-
al titles. We retained generic details such as the role of the
respondent as the member (including presidents) of a re-
search ethics committee or representative of a large phar-
maceutical company for the purpose of analysis but took
utmost care not disclose respondents’ identity. Before each
interview, we obtained oral informed consent and the per-
mission to record the interview on an audio device. The
average duration of interviews was 35 minutes; the range
was between 10 and 60 minutes. We anonymised all inter-
views at the level of transcription and saved each transcript
with a consecutive number such as T1, T2… for the trial-
ists whose trials were discontinued because of recruitment
problems, and R1, R2… for other respondents. Three re-
search associates who had signed the confidentiality agree-
ment transcribed each interview verbatim. PS verified each
transcript against the audio recording and resolved any dis-
parities or queries. We gave the respondents an opportunity
to review their interview transcript but all except two de-
cided against it. These two respondents added more details
to their original statements to improve the clarity but did
not remove any details.
Data analysis
PS and MB read the interview transcripts multiple times
to get a thorough understanding of the data. PS coded all
interviews using the analysis software MAXQDA version
12 and MB did the same manually. We carried out deduc-
tive coding guided by our main research question, which
was then built into thematic analysis [14]. The smallest
units of analysis were sub-codes, which were built into
codes. Codes were further merged with other related codes
to build themes. The codes and themes were continually
discussed within the research team to ensure agreement on
the iterative process of qualitative data analysis and to min-
imise bias due to subjective interpretation.
Results
After describing the characteristics of the respondents we
elaborate on four main themes with regard to reasons for
poor recruitment that are related to funding, health sys-
tems, investigators, and participants. We simultaneously
discuss ways in which these reasons could be addressed
drawing on suggestions from our respondents and propos-
ing several own ideas. We use select quotations from the
data to elaborate on these points. Our focus is not on how
many respondents stated the same reason or proposed the
same solution but to describe a spectrum of ideas obtained
through interviews and to facilitate discussion.
Profile of respondents
We interviewed a total of 12 academic clinicians with ex-
tensive experience of conducting clinical trials as principal
investigators or co-principal investigators. Six of these tri-
alists discussed specific details of their “failed” trials dis-
continued because of poor recruitment. Five out of these
six discontinued trials were investigator initiated and fund-
ed through SNSF, SAKK, professional organisations or a
department’s own research budget, whereas one trial was
industry sponsored. They included RCTs in the fields of
urology, diabetology, obstetrics, cardiac anaesthesiology,
pharmaceutical sciences and transplantation medicine. The
expected sample size for these six studies ranged between
70 and 300 but the actual sample of respondents included
ranged from 20 to 140 when the trial was discontinued.
All respondents reflected on reasons for discontinuation of
clinical trials irrespective of the type of intervention (phar-
maceutical product or medical device), the phase of the
clinical trials and the funding source for the study. How-
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ever, the focus of their reflections was on the compari-
son between investigator-initiated trials and large pharma-
ceutical industry-sponsored trials, which differ significant-
ly in terms of the research questions under investigation,
planned sample size, risk-benefit ratio for participants, ex-
pected outcome or the goal for conducting trial (obtaining
licensing approval from local or regional drug regulatory
authorities vs academic career step) and infrastructure and
human resource available for conducting the study.
In addition, we conducted interviews with six representa-
tives of the university hospital based Swiss CTUs, three
members/presidents of ethics committees, ten representa-
tives from pharmaceutical companies with long experi-
ence in planning and implementing large industry-spon-
sored clinical trials, two spokespersons from Swiss and
European Union (EU)-based patient organisations, two
representatives from the SNSF and the FOPH, and a repre-
sentative each from the SAKK and swissmedic. This het-
erogeneous group had experience of working in clinical re-
search in Switzerland, as well as in-depth understanding
of the global clinical research environment. This allowed
them to reflect on differences and similarities of conduct-
ing clinical trials in Switzerland as compared to the United
States or the EU. Many of these respondents had multiple
perspectives depending on their current or former profes-
sional role. For example, all three members/presidents of
ethics committees had conducted clinical trials themselves
in the past. Further, some of the industry representatives
had been academic investigators in their early profession-
al life and thus could retrospectively reflect on challenges
of conducting investigator-initiated trials in comparison to
their current role in planning and monitoring large multi-
centre industry-sponsored RCTs. We believe this diversi-
ty of perspectives helped us understand certain details and
nuances of conducting clinical trials in Switzerland.
Theme 1: Factors related to funding available for clini-
cal research
The most recurrent theme in discussion was challenges re-
lated to funding available for investigator-initiated trials
as compared to industry-sponsored trials. Our respondents
repeatedly stated that acquiring sufficient human and fi-
nancial resources for the entire duration of an RCT is the
biggest challenge for investigator-initiated trials. All re-
spondents were aware of the various funding schemes of
the SNSF and appreciated those possibilities. However,
they also expressed their concerns that clinical research re-
quires high professional standards which are quite chal-
lenging to achieve and sustain in academic settings unless
significant and continuous efforts are put into building
a professional workforce dedicated to clinical research
through education and training. Building such a workforce
takes decades of careful planning and systematic imple-
mentation, and needs to be addressed at the system level. It
requires building strong research infrastructure in univer-
sity hospitals, where clinical research should not be some-
thing that one carries out in addition to patient care but
is rather deeply integrated with it. The resources needed
for building such academic research centres and institu-
tions with an international reputation for high quality re-
search goes beyond the funding received by individual in-
vestigators to conduct a specific trial and yet is crucial to
encourage patients to participate in clinical research. They
further argued that training of research staff alone is not
sufficient, but systems must be in place to retain trained re-
searchers within academic settings by creating career op-
portunities and other incentives. Frequent turnover of clin-
ical trial staff in academic settings was mentioned as one
cause of a lower standard of clinical trial implementation.
The other parameter which links with availability of fund-
ing is the time clinicians can dedicate to their research-re-
lated activities. This is where human and financial resource
planning come into play as described below.
“…I think at the present time, research projects in academ-
ic settings are not given enough priority and also devoted
time. I very often see studies, protocols which we receive,
where we can guess that the clinician will not have time to
run this project by himself. There is no local funding. They
do that on – I don’t know in the 25th hour of the day. There
is no real help in infrastructure. And of course this has an
impact on recruitment, I guess. If you have a well-orga-
nized consultation, then patients are identified, let's say, by
a good and systematic way and so you don’t lose those pa-
tients. I think that can help.” (R28 Ethics committee mem-
ber)
Seven respondents highlighted the strategic importance of
trained and experienced study nurses and, in the context of
obstetrics, midwives, and commented on their rather limit-
ed involvement in the Swiss context as quoted below.
“What I don’t see enough used in Switzerland as a tool are
study or trial-nurses. I think that is a wonderful tool to get
better access to the patients and to keep them happier once
recruited for the simple reason that they have more time
and they don’t have these hierarchical barriers when talk-
ing to the patients.” (R24 Representative of patient organi-
zation)
Investigator-initiated RCTs often start out with optimism
but soon face practical challenges in recruitment. This
could be to the result of a number of factors, such as inade-
quate funding at the beginning of study (Swiss trialists R3
and R21), limited or no funding for the planning phase or
to undertake rigorous feasibility assessment (Swiss trialist
R16), inability of the principal investigator to procure ad-
ditional funding during the course of ongoing trial (Swiss
trialist T13) and errors in judgement by the principal inves-
tigators while planning the budget of the study (Swiss CTU
representative R1 and the trialists R8 and R11). The most
common reasons for a slower than expected rate of recruit-
ment were extremely rigid and narrow eligibility criteria,
ineffective screening of all potential patients to assess their
eligibility to be part of clinical trial, eligible patients refus-
ing to participate because of the increased burden associ-
ated with the study or the lack of any direct benefit. With-
out systematic screening of each eligible patient by a study
nurse or other physician colleagues, often the task of re-
cruitment falls on the principal investigator alone or is del-
egated to time-constrained assistant doctors. As a conse-
quence, recruitment frequently takes longer than expected,
yet available funds are being used as planned. If a principal
investigator is unable to procure additional funding for the
same research, they eventually must stop the trial. A few
respondents pointed out that increasing funding alone will
not change the situation and it should be coupled with bet-
ter assessment of protocols by funding bodies. This would
require funding bodies to recruit reviewers who are up-to-
date with current clinical research methodology, together
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with the senior academics who contribute their time and
experience.
“I would very much welcome that in the Swiss National
Science Foundation, there would be more people who un-
derstand clinical research. And not only purely medical
ones but health system research, and also the newer
methodologies, implementation science, which is I think
absolutely the future – very difficult but with much more
potential than just an RCT.” (T12 Swiss trialist sharing ex-
perience of specific discontinued trial)
One of the respondents sharply stated that studies without
proof of feasibility and a clear plan of recruitment based on
patient data should not be funded by any funding agency
to ensure fair utilisation of available resources (R10 CTU
representative). Another respondent insisted that funding
bodies such as SNSF or SAKK should mandate rigorous
feasibility data, as required by the pharmaceutical industry
(T13 Swiss trialist sharing experience of specific discon-
tinued trial). But it was also noted that significant time,
money and manpower is needed to monitor trial implemen-
tation at sites where an industry sponsor is not involved.
One respondent questioned the logic of initiating a large
number of trials in Switzerland that are not feasible owing
to low patient numbers and may not even have direct rele-
vance to the Swiss population. His argument was based on
better utilisation of available resources as described below.
“I also think – and that’s a very elitist (laughs) opinion,
that probably one should limit the number of clinical trials
that run in Switzerland. Switzerland is a small country and
we should focus on few really good trials. The numbers of
clinical trials have increased dramatically, we don’t have
more patients and we do have a bit more resources but not
in the same relation as the increase in trials. So I think to
achieve this, there should be more networking or more con-
nections between the large money givers for academic tri-
als, so that they really discuss together which are the im-
portant trials. And not someone supports part of one trial
and the other agency supports some part of another trial.
So 10 trials are partly funded but not one big trial where
really everyone is behind it. It is always difficult to decide
who should have the leading role in this. And in my opinion
this should be the SNSF. But it is not working at the mo-
ment of course. And there are many people who don’t think
this is the right thing to do.” (R20 Swiss trialist)
Theme 2: Healthcare system related factors
Switzerland with its decentralised healthcare system, spe-
cific regulatory requirements and comparatively small
numbers of patients per hospital faces unique challenges in
large international multicentre trials as described below.
“When it comes to big phase III trials, we are not compet-
itive at all. Because there they want to have a high input of
patients and there we are very handicapped for many rea-
sons. First, we have small hospitals. Even our big hospi-
tals are small hospitals. Zurich hospital is a small hospi-
tal compared to a hospital in Berlin or Vienna or Paris or
London. So we are not very competitive in terms of num-
bers of patients and type of patients. Then the second bur-
den is that Switzerland is very expensive. When we do mul-
ticentre studies at the amount they pay in Europe, we can
never pay our – the cost of a patient in Switzerland be-
cause, it’s almost half of the price in any other countries!
So they have to adapt for Switzerland the price. They don’t
like to do that. And then because it’s a small recruitment
or slow recruitment in Switzerland, they always start im-
plementing the studies in large countries like Poland, Ger-
many, France, Spain, Great Britain, Italy and come at the
last minute to Switzerland, to get 20–25 patients. We are
really a bit slow, we have few patients and we come late in
the introduction in the study. (T4 Swiss trialist sharing ex-
perience of specific discontinued trial)
Rather complex regulatory and ethics approval procedures
in Switzerland further slow down the agreement between
the sponsor of the trial and the local site, thus delaying re-
cruitment.
“…the second reason is we are highly regulated. So in oth-
er words, for any sponsor or even if you do investigator
initiated studies, to implement studies is exceedingly diffi-
cult as compared to others. The third one is the regulatory
aspects through Swissmedic which is different from other
European countries, is also an impediment. So there are
several hurdles which make it not so easy in Switzerland to
enrol patients into clinical trials or to be even considered
for international clinical trials. Why do we need ethics
committee approval in Bern, Zurich, Lausanne, Geneva?
Is ethics different in these cities? I would go even broader,
is it different in Europe or Western Europe? I mean, ba-
sically it doesn’t make sense. If you have a multicentre
protocol which may even have FDA oversight, then you
have specific details from the ethics committee in Bern. It
just does not make sense. It just costs time and impairs
the recruitment because we are frequently not considered
anymore, particularly because of the stringent oversight
from the Swiss ethics committees. I really think a major
limitation in Switzerland is the overregulation through the
ethics committees and Swissmedic and that one needs to
have a broader Pan-European perspective on the issue.”
(R21Swiss Trialist)
All respondents acknowledged and appreciated the role of
CTUs to standardise clinical trials in Switzerland, but a
few respondents challenged the idea that every trial must
be reviewed and approved by a CTU and raised concerns
about affordability of CTU services. In general, CTUs
were seen as guides and technical experts who helped
investigators write realistic protocols. Many respondents,
including representatives of large pharmaceutical compa-
nies, suggested that a database or a track record of all sites
involved in clinical trials in Switzerland, grouped by dis-
ease areas and special interests, would be highly valuable.
Such a database could help researchers who are interested
in a particular disease to get in touch with other researchers
working in that domain and also help industry sponsors
to identify sites with proven track record. All respondents
agreed that developing research networks is the best way
to strengthen clinical research in Switzerland. They often
described their positive experiences of doing research with
the SAKK or SwissPedNet but at the same time accepted
that development of effective research networks is a time
and labour intensive process and requires sustained moti-
vation and leadership.
The potential of smaller regional hospitals and clinics as
trial sites was highly debated. Some researchers felt that
these hospitals do not have the necessary administrative in-
frastructure or trained manpower and often do not recruit
a single patient whereas creating networks with other uni-
versity hospitals is easier and more successful. But there
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were also opposing views advocating inclusion of smaller
hospitals in clinical trials as demonstrated below.
“…. another access could be to involve regional hospitals
more depending on the type of research questions. Often
the doctors at regional hospitals, so non-university hospi-
tals, will be quite happy to collaborate in research; they
are just not in this milieu anymore and maybe they wish
they could. They are maybe a little bit forgotten or people
don’t think about their potential necessarily. So I am not
only thinking that collaborations should be between the
university hospitals, but also if there was a kind of net-
working mechanism, a way of signalling your interest in
xyz, that would then be visible and you could in this way
get involved in collaborative research if you are at a local
hospital. That may help too.” (R25 CTU representative)
Some of our respondents were concerned that many private
clinics and smaller hospitals in Switzerland are reluctant to
refer their patients who might be eligible for clinical trials
to trial sites (often large university hospitals and canton-
al hospitals) due to fear of losing a patient and the mon-
ey thereby. Two factors that need to be addressed here are
(1) ways to inform the clinicians in peripheral hospitals re-
garding ongoing trials and (2) to have agreements that the
patients will return to the referring hospital once their par-
ticipation in the trial is over. An up-to-date, easy-to-search
database of all registered and ongoing clinical trials could
address the first challenge provided that clinicians are sen-
sitised to regularly check such a database. The second chal-
lenge needs further scrutiny and discussion as it depends
on the patient’s choice and the arrangement with the health
insurance company.
Finally all respondents highlighted the importance of stan-
dardised medical records across Switzerland. Many of our
respondents felt that the recent development of a person-
alised health network in Switzerland could facilitate cre-
ation of a nationwide patient database, not just for rare
diseases but rather a unified system of electronic medical
records that are standardised nationally, accessible elec-
tronically and hence critical for feasibility assessment of
RCTs.
“The fact that there is not a unique identifier, number
for identification with exception of the AHV number in
Switzerland, is a limitation to communication between sys-
tems, between IT infrastructures. So that’s a point that is a
limitation, I would say, for multi-centric clinical research.
It’s a detail but I think there is an impact since clinical
database has an easy way to communicate, to screen peo-
ple and so on... Then at the institution level which is a
lower level but closer to the patients, I think a better inte-
gration of clinical research structures, once again homog-
enizing standard operating procedure, a type of software,
maybe sharing resources including human resources dedi-
cated to clinical research. I think integrating progressive-
ly the different clinical research structures that are existing
in one institution is of importance.” (R19 CTU representa-
tive)
Respondents of this study also discussed the importance of
trial registration and the creation of a comprehensive data-
base of ongoing trials accessible to all interested stakehold-
ers.
“Well firstly, I think that a national clinical trials registry
would help. A portal, where patients and doctors can find
and register to clinical trials, which is accessible, meaning
that it is on several different websites, like patient organi-
zation-websites, hospital-websites and different websites to
reach patients. And there could be done a lot more by pub-
lic institutions to raise awareness about clinical research
in Switzerland, and why it is important to participate in
such trials, not only for the society, but also for individ-
ual patients, so that they may get the best treatment if they
participate in trials. Often people don’t have this informa-
tion.” (R27 Representative FOPH)
One of the respondents who worked in The Netherlands
before moving to Switzerland was rather shocked to realise
that not all trials in Switzerland are registered. The respon-
dent argued that the trial registration and providing feed-
back on the progress of the trial to relevant authorities on
a regular basis is the responsibility and accountability of
each principal investigator and should be taken seriously.
“I think the hospital or the academic institution should
know about their own trials. I think that’s the minimum!
I mean basically I would even think that if ever an audit
looks into the competence of such a centre that they should
look into them. I mean imagine in the extreme case you
have a unit in a hospital which is not able to complete 50%
of their trials, right? And I think that’s a serious quality is-
sue! So if you get an audit then that means it needs to be
transparent. When there is something wrong with the qual-
ity of the investigators or with the structures or with some-
thing. I mean basically it’s the competence of the centre
when they cannot complete their trials.” (R31 Representa-
tive of pharmaceutical industry)
Theme 3: Investigator-related factors
Pertinent themes included challenges in developing collab-
orations with other Swiss hospitals and the way in which
success of clinicians is measured. These two factors are
linked in a number of ways. Given the small population,
high density of hospitals and smaller number of patients
per disease condition, it is critical that Swiss hospitals cre-
ate effective collaborations, research networks and effi-
cient referral systems for patients to the recruiting sites.
The general experience of the respondents was quite the
opposite, even though they all admitted that things are im-
proving. Three out of six trialists whose trials were dis-
continued because of poor recruitment had faced serious
challenges in establishing meaningful and functional col-
laborations with other hospitals or colleagues from differ-
ent disciplines from the same hospital as described below.
“Sometimes you have the feeling it’s easier to cooperate
with colleagues from the United States than with col-
leagues here in Switzerland. There is still not an extremely
cooperative feeling between some of the players here.” (T5
Swiss trialist sharing experience of specific discontinued
trial)
Researchers were divided in their opinions on how to fos-
ter meaningful collaborations. A few were of the opinion
that eventually it is a personal style and ability of a prin-
cipal investigator to connect with other researchers. Some
principal investigators can do it naturally and are often suc-
cessful in fostering collaborations. But others argued that
collaborative clinical research should not be solely based
on personal relationships established by the principal in-
vestigator with other colleagues as it is not sustainable in
the long run. Such trials run the risk of collapsing when
the principal investigator moves to another institution or
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gets busy with another trial of higher interest. This is where
academic recognition, competition, and award systems
come into play as explained by one respondent.
“….. we need fewer researchers but better quality re-
searchers. The way academia in medicine is set up, at least
in Switzerland, is wrong. Somebody who wants to pursue
a hospital career or wants to become a clinician leading a
division in a university hospital or in a regional cantonal
hospital; he or she has to do research to show that he or
she is an academic. I think this academic model is outdat-
ed. I think it would be much better if we have very skilled
clinicians who know how to apply clinical research and do
an excellent clinical job and few researchers who first of
all do not necessarily have to be MDs, they can also come
from other fields who do really good research and are well
trained. If they are really good, then you have to develop
career possibilities and funding for them and that is also
not sufficiently done here in Switzerland.” (R8 Swiss trial-
ist)
The system of promotion, recognition and career growth
makes researchers focus on their individual work and the
role as a principal investigator. But to be able to recruit pa-
tients in a large multicentre trial across Switzerland, one
needs effective and functional collaboration across differ-
ent centres. This requires a different set of skills and qual-
ities but, as expressed by one respondent, these skills and
qualities are not valued enough in the current system of
academic evaluations.
“…(here in Switzerland), it’s not usual that the university
clinics, the centres with certain specialties, combine to un-
dertake multicentre trials because everybody fears that he
or she will not get enough benefit. The smallness of the uni-
versity clinics and the individualised nature of people and
centres refrain them from sitting together and collaborat-
ing for a multicentre trial. If, for instance, succeeding in a
multicentre trial would be evaluated with additional added
value… credit; that would be something which is beneficial
for the CV of an individual that he successfully participat-
ed in a multicentre trial. And if participation is not diluted,
it’s even almost the opposite. This would change mentali-
ty quite a bit. I think even for the SNSF. It’s not a priori-
ty to perform multicentre trials and to foster, to encourage
collaboration between centres. In the Swiss context, the in-
dividual wants his career and thinks ‘If I contribute to a
multicentre trial, my own ambitions are not fulfilled.’” (T9
Swiss trialist sharing experience of specific discontinued
trial)
Theme 4: Participant/patient-related factors:
Switzerland with its population of about 8 million and a
comparatively high hospital density poses peculiar chal-
lenges in participant recruitment for RCTs. All interviewed
principal investigators highlighted this fact and linked it to
better access to healthcare and near saturation of therapeu-
tic options for most diseases as described below.
“I think if we would have performed this trial in Romania
or wherever in another country where the health care sys-
tem is not as well developed, then it would have been
easy to do it. Because it would be attractive to get this
high quality care and we could have recruited very rapidly
enough patients. I think it’s particularly a problem in
Switzerland when you do a clinical trial that patients have
already access to a very good healthcare system. This kind
of protocol is not suitable for Swiss patients. This kind of
intervention is not ideal, not very adequate for Swiss pa-
tients.” (T9 Swiss trialist sharing experience of specific
discontinued trial)
Two respondents stated that, unlike in the United States,
where patients and the general public demonstrate a com-
paratively strong drive and desire to be part of clinical
research either for financial reasons or to gain access to
healthcare which is otherwise inaccessible or unaffordable,
universal health coverage in Switzerland and availability
of many treatment options covered by health insurance
provides no incentives for patients to be part of clinical re-
search (R9 pharmaceutical industry representative and R29
representative of FOPH). The situation is slightly different
for Swiss patients with rare diseases but still not desperate
enough to push them to participate in clinical trials (R16
Swiss trialist and R32 representative from Swissmedic).
Half of respondents expressed their concern that many new
drugs are tested not in the Swiss population but elsewhere,
in eastern Europe, and that effectiveness and safety data
generated through those trials cannot be easily extrapolat-
ed to the Swiss population. They advocated that the Swiss
public and patients should engage more in clinical research
to improve treatment options and not just benefit from the
research which took place elsewhere. Six respondents fur-
ther attributed the reluctance of the Swiss population to be
part of clinical research to a negative coverage of clinical
trials in the media where often metaphors such as “human
guinea pigs” are used to talk about participants in clinical
trials. Any catastrophes, such as deaths and severe injury
of healthy volunteers participating in first-in-human trials
in Paris in January 2016, are discussed in rather one-sided
and sensational ways but other ongoing trials which are be-
ing carefully monitored and which contribute to improve-
ment of treatment options are underplayed in media dis-
course, thus influencing general public in a biased way. All
the respondents advocated improved engagement of the
general public in clinical research and drug trials. The fol-
lowing quotation provides some suggestions to start such a
process of engagement.
“I think all kinds of awareness-building activities that gov-
ernmental scientific organisations could put in place to
build awareness would be constructive. Clinical trials still
carry the old stigma of using patients as guinea pigs. You
know, to get over that, we could bring a new awareness to
the culture, that science is for everyone and that we need
everyone’s perspective to become a healthier environment
and better place to live! An idea would be to sponsor activ-
ities, research days, fun-family events, where information
can be given out and people can learn about the concept
of clinical trials and research and how clinical trials work
and how they benefit society in general, and that in some
cases it is very important directly for the patients (e.g., to
be able to have access to new medications not yet on the
market)….. Everyone knows about donating blood, right?
That is really now an accepted and positive part of our
culture. There are many blood-donation campaigns, some-
times conducted by hospitals, public health authorities, or
even large employers. The same way that they do blood
donation drives, you could do information dissemination
about clinical trials. I think also talking in schools, go-
ing to science teachers and offering to explain clinical re-
search would be informative and I think science teachers at
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schools would welcome that. I am familiar with the public
school system in the French speaking part of Switzerland
and expect they would be delighted to have someone come
and talk about research and science and to start giving in-
formation early to students.” (R26 Representative patient
organization)
Discussion
Main findings
This qualitative study revealed that Switzerland – with
its decentralised healthcare system, universal health cov-
erage and availability of many treatment options for pa-
tients, little collaboration between different stakeholders in
clinical research and underdeveloped research networks,
many research regulations, often negative media coverage
of clinical research, and lack of recognition for partici-
pating clinical researchers in large multi-centre projects –
faces particular challenges for successful recruitment of
patients to clinical trials. Limited human and financial re-
sources, especially in the academic setting further aggra-
vate the situation, and when funds are used up this typical-
ly triggers discontinuation of delayed clinical trials, which
were once initiated with a great deal of optimism but insuf-
ficient preparation. Trialists and other stakeholders in the
Swiss clinical research arena expressed the need for more
interactive structures and collaboration across stakeholders
to tackle the often interlinked problems.
Specifically, we argue that the funding and the human re-
sources available for investigator initiated trials in academ-
ic research settings should be treated as a scarce resource.
Though there are several recent initiatives and schemes
from the SNSF and the FOPH (see below), they alone can-
not make a difference unless there is clear prioritisation
and research agenda-setting at the national level, devel-
opment of research consortia and networks which under-
take coordinated and collaborative research, rigorous as-
sessment of feasibility of submitted research proposals,
and continuous monitoring of clinical trials taking place in
academic settings.
The Swiss healthcare system, funded and regulated at can-
tonal level, clearly influences the financing of hospitals in
each canton and health insurance costs across cantons. The
latter point is seen as a factor that limits the effective re-
ferral of patients from peripheral hospitals to the hospitals
with ongoing clinical trials for the purpose of trial partici-
pation, but this discussion is beyond the scope of the cur-
rent paper. Along similar lines, the decentralised ethics re-
view procedure in Switzerland has limitations. In addition
to the fact that protocols submitted to research ethics com-
mittees (RECs) often have scarce information on planned
recruitment, members of RECs might also struggle to chal-
lenge the feasibility of proposals submitted by their col-
leagues/peers from the university hospitals. Federal level
RECs specialised in different topics would allow review
by experts in a particular field and could overcome chal-
lenges more efficiently. University and cantonal hospitals
are in a strong position to undertake clinical research ow-
ing to the available research infrastructure, patients and re-
search-oriented health care professionals, provided hospi-
tal administration perceives and promotes the benefit of
research embedded in the clinical care set-up. Research
can be easily perceived as an expensive activity (rather
than a revenue-generating activity), which could compro-
mise the primary duty of healthcare professionals to care
for and treat their patients. But hospitals can also take
pride in their high quality research activities coupled with
evidence-based health care provision, thus attracting re-
searchers and healthcare professionals as well as patients.
Large amounts of data collected by health systems when
streamlined, stored and shared in uniform ways could sig-
nificantly contribute to health systems research and to im-
prove quality of healthcare provision.
Like hospitals, individual researchers need to balance their
role in clinical research and care. Many young clinicians
are interested in and driven by a research oriented mind-
set to improve the quality of care they can provide to their
patients, but they face a number of structural and career-
related challenges. Structural challenges need to be ad-
dressed at national and institutional levels, otherwise there
will be limited incentive and motivation for healthcare pro-
fessionals to undertake research activities. As pointed out
by a respondent, if only the first and last author publica-
tions count towards career assessment that is a clear hurdle
for researchers to be part of large research networks and
contribute to patient recruitment where they do not ben-
efit themselves in terms of personal career development.
We must point out that career assessment criteria need to
be streamlined and clarified in an international context and
not just in Swiss settings. This is particularly crucial in
today’s globalised research arena and highly mobile (in
terms of geography and disciplines) research careers.
We do not argue or support the claim that lack of access to
healthcare or misplaced belief that trial participation will
provide therapeutic benefit should drive patients to partic-
ipate in clinical trials. But we do believe that a change in
mind-set of the general population, including that of pa-
tients, is needed in Swiss society. We cannot expect to ben-
efit solely from research carried out in other parts of the
world and built on contributions of patients from those
countries, for two main reasons. First, with genetic, eth-
nic and general health profile variations in a population
where particular drugs are tested, findings cannot be al-
ways extrapolated to other populations where a drug be-
comes available after licensing. Second, as a society we
should also be willing to share the burden of research par-
ticipation and to engage in the entire research endeavour
from priority setting to research planning, implementation
and dissemination of outcomes of research. There is al-
so evidence that Swiss patients consider, on average, clin-
ical research positively (see table 2 in [15]). We believe
that researchers, clinicians, media and communication ex-
perts and patient groups have an important role to play. Fi-
nally, not every healthcare research study involves signif-
icant burden or risks, yet the willingness of a population
and patients to share their anonymised medical data and
personal information combined with a streamlined coun-
try-wide electronic medical record system could facilitate
a vast body of research to strengthen health systems and to
improve the health of patients and the population.
Strengths and limitations
The use of qualitative interviews with a broad range of
clinical research stakeholders in Switzerland represents a
major strength of our study which permitted to generate
new and unique findings. The interviews provided real in-
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sights into the lived experience of conducting clinical trials
including the perspective of investigators whose trials were
discontinued prematurely due to insufficient recruitment.
Open-ended interview questions allowed respondents to
elaborate on their viewpoints on how to prevent recruit-
ment failure and to improve the Swiss clinical research
environment in greater detail. We believe that the fact of
having two interviewers conducting all the interviews in
English and listening to each other’s interview recordings
improved the consistency and standardisation of the inter-
view technique. Analysis of the interviews by generating
codes and building themes was carried out by the research
team to minimise systematic bias that could have arisen if
the data had been analysed by only one researcher. Previ-
ous quantitative studies were limited in their exploration of
risk factors for poor recruitment because their small num-
ber of variables allowed for a rather superficial view only
[1, 16]. In addition, our approach overcomes problems of
syntheses of qualitative evidence, that are frequently lim-
ited by the poor reporting of recruitment detail in the in-
cluded trial reports and their inability to consider evidence
from unpublished RCTs [12]. Our study adds to the scarce
evidence base on how recruitment to clinical trials was
planned and conducted in practice [5, 17]. We employed
purposive sampling to access a wide spectrum of view-
points that strengthened our findings.
However, there were 22 Swiss trialists and 4 other Swiss
stakeholders who did not reply to our emails or declined
participation. Whether the views of those 26 persons (40%
of invited) are substantially different from those who were
interviewed is unclear. Some explained their refusal by
their extremely busy schedules and priority given to other
tasks, but reasons may, at least in part, include the consid-
eration that openly discussing and analysing failures is not
popular in the research community. According to a recent
cross-sectional survey in Switzerland, patient enrolment
and logistical problems top the list of difficulties in clinical
research in general – not only in RCTs [18]; i.e., the inves-
tigated difficulties with clinical trials could be the symp-
toms of a more general problem related to acceptance of
clinical and population research in medicine, which, how-
ever, is beyond the scope of this study. Finally, to tease out
particularities of the Swiss clinical research arena was part
of the study aim inherently limiting extrapolation of find-
ings to other countries.
Recent developments in the Swiss clinical trial context
Since we started conducting interviews for this study in
August 2015 there have been recent developments at the
SNSF and FOPH with promising initiatives that partially
address some points mentioned by interviewed stakehold-
ers who might not have been aware of those initiatives
at the time of interview: (1) In August 2015 the SNSF
launched a special program “Investigator Initiated Clinical
Trials (IICT)” for the first time to enable independent clin-
ical researchers to answer clinical questions that are im-
portant for patients [19]. The yearly budget of the SNSF
for 4–8 industry-independent clinical trials is about CHF
10 Mio. (2) The recent SNSF initiative "Protected Re-
search Time for Clinicians" (PRTC) is intended to help
especially younger clinicians to dedicate at least 30% of
their working time to their research project funded by the
SNSF [20]. (3) A task force deployed by the FOPH de-
veloped the 2016–21 roadmap for building up the future
generation of clinical researchers which is “designed to
help close gaps in the career track for clinical researchers
and provide them with opportunities for efficient high-
level training” [21]. Responsibility for implementing the
roadmap is shared by the local MD-PhD graduate schools,
the SCTO with its network of CTUs, the Swiss Academy
of Medical Sciences, the FOPH and unimedsuisse. (4) The
FOPH launched the Swiss National Clinical Trials Portal
(SNCTP) that replaced a not user-friendly previous data-
base for Swiss clinical trials [22]. The SNCTP displays tri-
als submitted on the Business Administration System for
Ethics committees (BASEC) platform in real time as soon
as they are approved by the ethics committee. The FOPH
further planned to add lay summaries and to continuously
improve the utility of the tool.
Comparison with other studies and implications
Although various studies have already investigated barri-
ers to and facilitators of recruitment [2–11], only one of
these focused specifically on the Swiss context. A postal
survey by Spaar et al. was conducted among 55 recruiting
physicians of a Swiss multicentre trial on respiratory re-
habilitation strategies in patients with chronic obstructive
pulmonary disease [5]. Based on the 35 useable returned
questionnaires they found that “time constraints” was per-
ceived as the most relevant recruitment barrier by recruit-
ing physicians followed by “difficulties including identi-
fied eligible patients”. These points were also evident in
our interviews with trialists and were mentioned in sur-
veys from the physicians’ perspective in other clinical set-
tings highlighting their general importance independent of
a Swiss context [4, 23]. Moreover, high quality evidence
on particular interventions aiming at patient recruitment
is sparse and more methodological empirical research em-
bedded in clinical trials is needed [24–27]. Another report
by Weisskopf et al. suggested a set of tools in the clinical
information system of the University Hospital Zurich that
may (among other advantages) also improve the planning
and conduct of patient recruitment to trials [28]. This ini-
tiative and the already mentioned recent developments of
new support programmes by the SNSF and the FOPH
are promising; however, the effectiveness of the new pro-
grammes and initiatives needs to be evaluated with quanti-
tative and qualitative indicators in order to allow confirma-
tion or change of strategies. We believe that further large
collaborative efforts across various stakeholders in clinical
trials appear necessary to sustainably improve patient re-
cruitment in RCTs in Switzerland. All stakeholders seem
to agree on the importance of the problem but it seems less
clear whether they are prepared to take further responsibil-
ity and action in a commonly agreed collaborative plan.
Conclusions
This exploratory analysis of 39 interviews with Swiss tri-
alists and other stakeholders on reasons and potential so-
lutions for insufficient recruitment of participants to clini-
cal trials in Switzerland revealed various country-specific
particularities that contribute to the problem and are main-
ly related to four themes: the healthcare system, availabil-
ity of funding, roles and attitudes of investigators, and the
participants’ perspective. In addition to recent promising
developments at the SNSF and FOPH, agreement on com-
Original article Swiss Med Wkly. 2017;147:w14556
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 8 of 10
mon goals and concerted efforts by the involved stakehold-
ers appear necessary to achieve improvement.
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Appendix 1 Interview guides
The interview guides are available as a separate file at
https://smw.ch/en/article/doi/smw.2017.14556
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